US0953061068 - Common Stock

**BLBD** gets a fundamental rating of **5** out of 10. The analysis compared the fundamentals against 130 industry peers in the **Machinery** industry. **BLBD** has an average financial health and profitability rating. **BLBD** is not valued too expensively and it also shows a decent growth rate.

In the past year **BLBD** was profitable.

In multiple years **BLBD** reported negative net income over the last 5 years.

The reported operating cash flow has been mixed in the past 5 years: **BLBD** reported negative operating cash flow in multiple years.

With an excellent **Return On Equity** value of **75.80%**, **BLBD** belongs to the best of the industry, outperforming **99.22%** of the companies in the same industry.

Looking at the **Return On Invested Capital**, with a value of **33.82%**, **BLBD** belongs to the top of the industry, outperforming **99.22%** of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 17.57% | ||

ROE | 75.8% | ||

ROIC | 33.82% |

ROA(3y)-2.3%

ROA(5y)0.72%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

Looking at the **Operating Margin**, with a value of **9.72%**, **BLBD** is in line with its industry, outperforming **51.56%** of the companies in the same industry.

In the last couple of years the **Operating Margin** of **BLBD** has grown nicely.

The **Gross Margin** of **BLBD** (**17.69%**) is worse than **74.22%** of its industry peers.

In the last couple of years the **Gross Margin** of **BLBD** has remained more or less at the same level.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | 9.72% | ||

PM (TTM) | 6.36% | ||

GM | 17.69% |

OM growth 3Y22.15%

OM growth 5Y5.9%

PM growth 3Y14.85%

PM growth 5Y-5.7%

GM growth 3Y3.86%

GM growth 5Y0.59%

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so **BLBD** is creating value.

Compared to 1 year ago, **BLBD** has more shares outstanding

Compared to 5 years ago, **BLBD** has more shares outstanding

Compared to 1 year ago, **BLBD** has an improved debt to assets ratio.

An Altman-Z score of **6.79** indicates that **BLBD** is not in any danger for bankruptcy at the moment.

The Debt to FCF ratio of **BLBD** is **0.82**, which is an excellent value as it means it would take **BLBD**, only **0.82** years of fcf income to pay off all of its debts.

Even though the debt/equity ratio score it not favorable for **BLBD**, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.88 | ||

Debt/FCF | 0.82 | ||

Altman-Z | 6.79 |

ROIC/WACC3.86

WACC8.77%

A Quick Ratio of **0.56** indicates that **BLBD** may have some problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.23 | ||

Quick Ratio | 0.56 |

Looking at the last year, **BLBD** shows a very strong growth in **Revenue**. The Revenue has grown by **26.17%**.

Measured over the past years, **BLBD** shows a small growth in **Revenue**. The Revenue has been growing by **2.02%** on average per year.

EPS 1Y (TTM)471.79%

EPS 3Y9.28%

EPS 5Y-8.41%

EPS Q2Q%229.63%

Revenue 1Y (TTM)26.17%

Revenue growth 3Y8.81%

Revenue growth 5Y2.02%

Sales Q2Q%15.38%

The **Earnings Per Share** is expected to decrease by **-16.90%** on average over the next years. This is quite bad

The **Revenue** is expected to grow by **11.78%** on average over the next years. This is quite good.

EPS Next Y171.21%

EPS Next 2Y72.29%

EPS Next 3Y-16.9%

EPS Next 5YN/A

Revenue Next Year18.79%

Revenue Next 2Y14.72%

Revenue Next 3Y8.58%

Revenue Next 5Y11.78%

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

A **Price/Earnings** ratio of **18.56** indicates a rather expensive valuation of **BLBD**.

Based on the **Price/Earnings** ratio, **BLBD** is valued a bit cheaper than 65.63% of the companies in the same industry.

When comparing the **Price/Earnings** ratio of **BLBD** to the average of the S&P500 Index (**28.63**), we can say **BLBD** is valued slightly cheaper.

The **Price/Forward Earnings** ratio is **16.94**, which indicates a correct valuation of **BLBD**.

Based on the **Price/Forward Earnings** ratio, **BLBD** is valued a bit cheaper than 60.16% of the companies in the same industry.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 18.56 | ||

Fwd PE | 16.94 |

The rest of the industry has a similar **Enterprise Value to EBITDA** ratio as **BLBD**.

80.47% of the companies in the same industry are more expensive than **BLBD**, based on the **Price/Free Cash Flow** ratio.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | 14.54 | ||

EV/EBITDA | 12.76 |

The low **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A cheap valuation may be justified as **BLBD**'s earnings are expected to decrease with **-16.90%** in the coming years.

PEG (NY)0.11

PEG (5Y)N/A

EPS Next 2Y72.29%

EPS Next 3Y-16.9%

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**BLUE BIRD CORP**

NASDAQ:BLBD (6/21/2024, 7:00:01 PM)

After market: 53.82 0 (0%)**53.82**

**-0.81 (-1.48%) **

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryMachinery

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap1.74B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | 18.56 | ||

Fwd PE | 16.94 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)0.11

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | 17.57% | ||

ROE | 75.8% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | 9.72% | ||

PM (TTM) | 6.36% | ||

GM | 17.69% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover2.76

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 0.88 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.23 | ||

Quick Ratio | 0.56 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)471.79%

EPS 3Y9.28%

EPS 5Y

EPS Q2Q%

EPS Next Y171.21%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)26.17%

Revenue growth 3Y8.81%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y